Anthropic has released Claude Science, a version of its large language model configured specifically for scientific laboratories and pharmaceutical research operations, becoming the first large artificial intelligence developer to offer a separate interface and product built for scientists. The company has also disclosed plans to develop its own drugs, treating the new platform as a foothold in a broader competition to shape the future of biology. At the same time, President Trump's effort to make U.S. prescription drug prices the world's lowest is running up against the realities of mid-sized pharmaceutical companies, whose business models make industry-wide price agreements far harder to strike.
What Claude Science Is and Why Pharma Is the Target
Claude Science is Anthropic's answer to a specific demand: pharmaceutical and scientific research teams need AI tools calibrated for laboratory workflows, not general conversation. By releasing a dedicated interface rather than asking lab scientists to adapt a general-purpose model, Anthropic is signaling that it sees drug discovery as a core market, not a secondary application.
The company goes further than software, however. Anthropic has announced intentions to develop drugs of its own — a step that would place the AI firm inside the pharmaceutical pipeline it is also supplying to industry clients. The combination of platform provider and internal drug developer is unusual, and questions about competitive dynamics will only sharpen as the company's biology ambitions become clearer.
Most-Favored-Nation Drug Pricing and the Mid-Market Gap
Most-favored-nation pricing is a straightforward concept: the United States pays no more for prescription drugs than the lowest price offered to any other developed country. President Trump made this the centerpiece of his pledge to deliver the world's cheapest drug prices for American patients, and the administration secured agreements from 17 of the largest global drugmakers to participate on those terms.
The complication is structural. Mid-sized and smaller pharmaceutical companies are responsible for developing most new innovative medicines, and they were not part of the initial wave of agreements. A closely watched Medicaid pilot program is now probing whether those companies can be brought in. Unlike the large drugmakers that negotiated the opening deals, mid-size firms lack the broad product portfolios that allow a company to absorb lower prices on some drugs while protecting margins elsewhere. Their different business models make the arithmetic of concession harder, and the pilot's outcome will determine how much of the prescription drug market the most-favored-nation framework can realistically reach.